Generate Biomedicines (NASDAQ:GENB) Shares Gap Up – Here’s What Happened

Generate Biomedicines Inc (NASDAQ:GENB) gapped up before the market opened on Thursday . The stock had previously closed at $13.02, but opened at $13.62. Generate Biomedicines shares last traded at $13.5090, with a volume of 212,549 shares trading hands.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GENB shares. Cantor Fitzgerald started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating for the company. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. The Goldman Sachs Group started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 target price for the company. Guggenheim started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Zacks Research raised shares of Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Up 4.9%

The firm’s 50-day moving average is $12.94.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.